4145 Studies have shown that GLP-1 and its receptor agonists not only inhibit the levels of total cells, neutrophils, macrophages, eosinophils, lymphocytes, TNF-, IL-4, IL-5 and IL-13 in mouse alveolar lavage fluid 46 but also mediate anti-inflammatory effects through stress-activated protein kinase (JNK) inhibition, signal transducer and activator of transcriptional activator protein 3 (STAT3) activation and cAMP/PKA/NF-B signaling pathways, reducing the release of pro-inflammatory markers (iNOS, IL-1, IL-6, TNF- and monocyte chemotactic protein-1 (MCP-1), MMP-2, MMP-9, ROS) and increasing the release of anti-inflammatory markers (IL-10, mannose receptor-1 (MRC-1), arginine-1 (Arg-1) release as well as prostaglandin E2 (PGE2) and cyclooxygenase 2 (COX2) mRNA and COX2 protein levels, 42,46 thereby achieving a reduced inflammatory response
Accessed Apr 14, 2025
(PubMed) Olsen SF, Sorensen JD, Secher NJ, et al
Before sticking the needle into the vial, always clean the top of the vial with a NEW alcohol wipe
While much of the public has focused on the remarkable effects of GLP-1 agonists for many people living with obesity, an even more remarkable story has largely escaped notice
Opportunities for Ingredient Companies The GLP-1 trend presents significant opportunities for ingredient and food supplement companies, particularly those producing natural GLP-1 inducers such as prebiotic fibers, berberine, resveratrol, curcumin, and ginseng
